April 16, 2007
Quest Diagnostics Incorporated has signed a definite agreement to acquire AmeriPath Inc in an all cash transaction valued at $2 billion.
The lab giant will assume $770 million in debt of the company that provides dermatopathology, anatomic pathology, and esoteric testing.
AmeriPath operates three divisions; Dermpath Diagnostics, which interoperates 2.4 million biopsies annually; AmeriPath, focusing on gastroenterology, urology, oncology, and women’s health; and Specialty Laboratories, an esoteric testing business.
The deal is expected to be completed in the second quarter of this year and is subject to regulatory clearance as well as other conditions.
For more information, visit Quest’s Web site.
